Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | PCSK9 | Q8NBP7 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | AHR | P35869 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12850750 | 0.88 | GPR84 (0.79) | GPR84HTR2AAHRLMNAHTR6 | |
| SCHEMBL3083899 | 0.87 | GPR84 (0.71) | GPR84TP53HTR2AAHRLMNA | |
| SCHEMBL31744727 | 0.85 | GPR84 (0.69) | GPR84TP53HTR2AAHRLMNA | |
| SCHEMBL5881100 | 0.84 | GPR84 (1.00) | GPR84PCSK9HTR2AAHRLMNA | |
| SCHEMBL3090757 | 0.83 | GPR84 (0.65) | GPR84TP53HTR2AAHRLMNA | |
| SCHEMBL3091118 | 0.83 | GPR84 (0.65) | GPR84HTR2AAHRHTR6KMT2A | |
| SCHEMBL3073688 | 0.83 | GPR84 (0.65) | GPR84PCSK9HTR2AAHRLMNA | |
| SCHEMBL22768845 | 0.80 | GPR84 (0.61) | GPR84TP53HTR2AAHRLMNA | |
| SCHEMBL18088437 | 0.78 | TP53 (0.66) | GPR84TP53HTR2ALMNAHTT | |
| SCHEMBL29202611 | 0.77 | GPR84 (0.66) | GPR84TP53PCSK9HTR2AAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207134-B2 | Fused ring spiroketal derivative and use thereof as anti-diabetic drug | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2048152-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | REN, WNK1, GCKR | GPR84 2377/4885TP53 4276/4885PCSK9 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.